Bimekizumab Efficacy through Year 1 in Patients With Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3 3B Trials. J of Skin 2024, 8 (2), s369. https://doi.org/10.25251/skin.8.supp.369.